Efgartigimod Alfa + Immunoglobulin Products Interaction

Moderateinteraction on record

Description

Concomitant use may lower systemic exposures and reduce effectiveness of immunoglobulin products. Closely monitor for reduced effectiveness.

Mechanism

VYVGART binds to human neonatal Fc receptor (FcRn), which may lower systemic exposures of FcRn-binding medications

Source: NLP:efgartigimod alfa